Clinical trials: COVID-19 Lower Respiratory Infection
COVID-19
DAS181 for STOP COVID-19
It is a multicenter, randomized, placebo-controlled, double-blind study. The study population is defined as subjects diagnosed with lower respiratory tract COVID-19 who require supplemental oxygen ≥2 LPM at the time of…
- Trial name
- NCT04354389
- Testing
- DAS181
- Where
- 2 sites in Italy
- Sponsor
- Ansun Biopharma, Inc.
COVID-19 Lower Respiratory Infection
Phase I/II Study of COVID-19 DNA Vaccine (AG0302-COVID19 High-dose)
This study will assess the safety and immunogenicity of AG0302-COVID19 in healthy volunteers.
- Trial name
- NCT04993586
- Testing
- AG0302-COVID19 for Intramuscular Injection, AG0302-COVID19 for Intradermal Injection
- Where
- 6 sites in Japan
- Volunteers
- 422 people, healthy volunteers welcome
- Sponsor
- AnGes, Inc.
Lower Respiratory Tract Infection, Parainfluenza
Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
This study will seek to enroll immunocompromised patients with Lower Tract parainfluenza infection. It also contains a sub-study to enroll patients with severe COVID-19.
- Conditions
- Lower Respiratory Tract Infection, Parainfluenza, Immunocompromised, COVID-19
- Trial name
- NCT03808922
- Testing
- DAS181, DAS181 COVID-19, DAS181 OL
- Where
- 28 sites in United States, Australia and 3 more
- Volunteers
- 274 people
- Sponsor
- Ansun Biopharma, Inc.
Influenza Infection, SAD-RV Infection and COVID-19
DAS181 for Patients With Severe Hospitalized Flu and SAD-RVs (COVID-19)
This is a Phase IIb study consisting of two cohorts to evaluate efficacy, safety and pharmacokinetics of DAS181 in IFV infection. An approximate total of 280 subjects will be enrolled into this study.
- Trial name
- STOP-Flu (NCT04298060)
- Testing
- DAS181
- Where
- China
- Volunteers
- 280 people
- Sponsor
- Ansun Biopharma, Inc.
COVID-19
A First-In-Human Phase 1b Study of AmnioPul-02 in COVID-19 / Other LRTI
This is a first-in-human (FIH), Phase 1b, open-label, dose-escalation, safety trial consisting of 3 dose levels. Subjects will always be treated in cohorts of size 3, with from 3 up to 6 cohorts i.e. 9-18 subjects.
- Trial name
- NCT05348772
- Testing
- AmnioPul-02
- Where
- Sweden
- Volunteers
- 6 people
- Sponsor
- Amniotics AB
Covid19, COVID-19 Lower Respiratory Infection
In-patient COVID-19 Study of Intranasal Foralumab
This is a Phase 2, randomized, placebo-controlled, double-blind, proof-of-concept study of intranasal foralumab in hospitalized subjects with severe COVID-19 and pulmonary inflammation.
- Conditions
- Covid19, COVID-19 Lower Respiratory Infection, COVID-19 Respiratory Infection
- Trial name
- NCT04983446
- Testing
- Foralumab
- Sponsor
- Tiziana Life Sciences LTD